ANGIODYNAMICS INC quarterly report, Q3 FY2014

Vollständiges Dokument

AngioDynamics, Inc. — Form 10-Q Summary

Reporting period: Fiscal third quarter and nine months ended February 28, 2014 (the filing was signed April 9, 2014). AngioDynamics designs, manufactures and sells medical devices for vascular access, peripheral vascular disease, oncology and surgery.

Financial performance

  • Third quarter: Revenue was $88.2 million, up 8.1% year over year. Gross profit was $45.6 million and gross margin 51.7%, compared with 50.5%. Operating income was $7.6 million versus $0.1 million; net income was $5.1 million, or $0.14 diluted EPS, versus a $1.0 million net loss, or $0.03 loss per share.
  • Nine months: Revenue was $260.4 million, up 3.3%. Gross profit was $133.0 million and gross margin 51.1%, compared with 49.5%. Operating income was $10.4 million versus $5.9 million; net income was $4.6 million, or $0.13 diluted EPS, versus $0.3 million, or $0.01 per share.
  • Revenue mix: Third-quarter Peripheral Vascular sales rose 11% to $47.4 million; Vascular Access rose to $27.3 million; Oncology/Surgery rose 15% to $12.0 million. For the nine months, Peripheral Vascular grew 8% to $141.7 million, Vascular Access declined 2% to $78.1 million, and Oncology/Surgery rose 6% to $35.7 million. U.S. sales were $206.5 million for the nine months; international sales were $49.1 million.
  • Cash flow: Nine-month operating cash flow was $15.2 million, compared with $15.5 million. Investing used $13.0 million and financing used $16.7 million. Cash declined $14.4 million to $7.4 million.
  • Liquidity and debt: At February 28, cash and cash equivalents were $7.4 million and marketable securities $1.8 million. Total debt was approximately $138.9 million: $5.0 million current term debt, $92.5 million long-term term debt and $41.4 million revolving debt. Revolver availability was $58.6 million. Management said available cash, investments, operating cash generation and revolver capacity should meet anticipated capital needs for at least 12 months.
  • Other balance-sheet items: Current assets were $140.1 million and current liabilities $63.4 million. Contingent acquisition consideration totaled $68.0 million, including $12.1 million current and $55.8 million long term. The filing estimates approximately $80.1 million of undiscounted future contingent payments.

Changes and management commentary

  • Quarterly revenue gains reflected EVLT procedure kits, AngioVac and microwave products; RFA and supply-agreement sales declined. Nine-month growth also included AngioVac and EVLT gains, partly offset by lower RFA, Habib and supply-agreement sales.
  • Gross margin improved with better operating efficiencies and product mix; the nine-month comparison also benefited from $3.8 million of prior-year Navilyst inventory step-up amortization.
  • Sales and marketing expense increased as the company expanded sales forces and added AngioVac clinical specialists. R&D spending increased, particularly for clinical trials and product development.
  • A $5.0 million third-quarter benefit from revaluation of Vortex contingent consideration materially supported operating income. The adjustment was based on revised sales forecasts and is a non-cash, estimate-sensitive item.
  • In September 2013, the company refinanced debt with five-year secured facilities: a $100 million term loan and a $100 million revolving facility. It reported compliance with financial covenants at February 28, 2014. Debt is secured by substantially all company and guarantor assets; interest margins rise with leverage.

Outlook, risks and contingencies

  • The company’s operational excellence program targets $15–$18 million in savings over three years. It anticipates approximately $4.7 million in restructuring charges, $5.4 million of facility investment and reductions of about 80–100 New York positions, alongside plant consolidation and operational initiatives.
  • No specific revenue or earnings guidance was provided. Management said it expects continued R&D investment and identified product mix, pricing pressure, new technologies and manufacturing efficiency as factors affecting margins.
  • Regulatory matters remain a risk. The January–February 2014 Queensbury FDA inspection resulted in one observation, which the filing says was corrected and verified during inspection. A separate Glens Falls inspection completed March 31, 2014 resulted in three observations; the company said it would respond. The filing warns unresolved FDA matters could lead to further regulatory or legal action, including product restrictions, recalls or penalties.
  • In March 2014, after the quarter end, a court entered a $74.9 million judgment in AngioDynamics’ favor against Biolitec-related defendants. Collection and outcome are not established by the filing; a related bankruptcy-court trial was scheduled for June 2014. A separate Bard patent case was stayed pending Patent Office appeals; no loss accrual was recorded because a loss was not then considered probable and reasonably estimable.
  • Goodwill and the NAMIC trademark were not impaired in the December 2013 annual tests, but their estimated fair values exceeded carrying values by only 6%; impairment estimates depend on significant assumptions. Two failed-auction municipal securities totaling about $1.8 million remain illiquid, although issuers were current on interest payments.
  • Management identified risks including regulatory action, litigation, product development and market acceptance, competition and pricing, economic conditions, foreign exchange and acquisition integration. It reported no material changes to the risk factors in the prior Form 10-K.

Most important facts to verify

  • Whether revenue growth and improved gross margins persist, particularly given product-level declines and the one-time contingent-consideration revaluation benefit.
  • Cash conversion and working-capital trends: receivables and inventory increased, while cash fell to $7.4 million.
  • Debt covenant headroom, refinancing costs and the ability to meet scheduled debt service as leverage-based interest margins can rise.
  • Realization and timing of the stated operational savings, against restructuring costs, facility investment and planned workforce reductions.
  • Resolution of FDA observations and litigation, including collectability of the $74.9 million Biolitec judgment and the Bard case.
  • Assumptions underlying contingent earn-out liabilities, goodwill and intangible asset valuations, and future cash tax benefits from net operating loss carryforwards.